European Urology remains at the top of our field in Nephrology and Urology! With the new IF of 25.2, over 2 million website downloads, and 40.7k followers on Twitter we are constantly striving to be a cut above the rest! Thank you to our Authors, Reviewers, and Readership!

SPOTLIGHT: Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma by Carissa E. Chu et al #UroSoMe #MedTwitter #UrothelialCarcinoma #EURUROL #spotlight #EditorsChoice

Our AI-powered platform helps you deliver digital innovation faster and with less risk by providing a fundamentally better approach to test automation.

🧬 Urine tumor DNA to stratify recurrence risk after atezolizumab in BCG-unresponsive NMIBC In a secondary analysis of the SWOG S1605 trial, urine tumor DNA (utDNA) profiling with the UroAmp assay was used to stratify the risk of response to treatment with atezolizumab in

🔬 Exploratory analysis of the KEYNOTE-045 study published in European Urology This post hoc analysis by Ronald de Wit examined whether the efficacy of second-line pembrolizumab, compared with chemotherapy, varied according to patients’ prior response or the type of

Spotlight: Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial by Emmeli Palmstedt et al #Spotlight #Medtwitter #UroSoMe #PCa #ProstateCancer

Spotlight: Erectile Dysfunction Update on Clinical Management by Paolo Capogrosso et al #Spotlight #Medtwitter #UroSoMe

Spotlight: Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors by Alessandro Larcher et al #Spotlight #Medtwitter #UroSoMe #RenalCancer

🧠 Word of Wisdom Wednesday Hypoxia-inducible factors (HIFs) play a pivotal role in tumor biology, but their emerging link with endogenous retrovirus activation opens new questions on the interplay between hypoxia, immune signaling, and tumor immunogenicity. This Word of Wisdom

🚨 Post-hoc analysis of ARASENS trial in European Urology A post hoc analysis of the phase 3 ARASENS trial explored postprogression outcomes after treatment with darolutamide + docetaxel + ADT versus docetaxel + ADT in men with metastatic hormone-sensitive prostate cancer

🔍 New in European Urology Computational histology AI improves risk stratification in high-grade Ta NMIBC In a multicenter cohort, the Computational Histology Artificial Intelligence (CHAI) assay outperformed current EAU and AUA risk models in predicting recurrence and

💡 Words of Wisdom Wednesday A new Word of Wisdom in European Urology discusses the landmark NEJM study by McHugh et al. on polygenic risk scores (PRS) for prostate cancer screening. PRS-based approaches significantly improved the detection of clinically significant prostate

New in European Urology By @OncoBellmunt Final subgroup analysis from the JAVELIN Bladder 100 trial confirms the long-term survival benefit of avelumab first-line maintenance in patients with nonvisceral or lymph node–only metastatic urothelial carcinoma (mUC). 🔹 OS: 31.4 vs

🔹 Final PRO Analysis from the MAGNITUDE Trial – Niraparib + AAP in BRCA1/2-altered mCRPC The phase 3 MAGNITUDE trial evaluated patient-reported outcomes in men with BRCA1/2-altered mCRPC treated with niraparib + abiraterone acetate + prednisone (AAP) versus placebo + AAP.

#RenalCancer #Epidemiology Update: #Incidence, #Mortality, #Survival, #GeneticPredisposition, and #RiskFactors • 🌍 434,840 cases and 11,953 deaths in 2022 • 📈 Incidence projected to increase by +72% by 2050 • 📈 Mortality projected to increase by +96% by 2050 • 📊

🚀 New in European Urology – Surgery in Motion Single-port Antegrade Robotic Lymphadenectomy (SPARL): a new frontier for minimally invasive management of lymph nodes in penile cancer. Through a single infraumbilical incision, SPARL allows bilateral inguinal ± pelvic

💡 New Word of Wisdom on European Urology by @Ostherpaller The STENTS randomized trial investigated whether stent omission after uncomplicated ureteroscopy improves recovery and patient comfort. 🔹 Omitting the stent led to significantly fewer urinary symptoms and pain 🔹 No

🧠 New in European Urology Erectile Dysfunction: Update on Clinical Management by @paolo_capog et al. @maartenalbersen @castiglionfabio Eur Urol. 2025;88:388–399 👉 https://t.co/DI6XHcFpFS This comprehensive review summarizes current and emerging strategies in the management of

💬 Platinum Priority Editorial – Discrepancy Between rPFS and PROs in PARPi Trials An insightful editorial by @tiahigano highlights the gap between radiographic progression-free survival (rPFS) and patient-reported outcomes (PROs) in PARP inhibitor combination trials such as

🧠 Insightful exchange in #EurUrol How reliable is PSMA PET–based risk stratification across tracers and disease stages? Pan et al. raise critical points on the PPP2 model by Karpinski et al.—a valuable discussion shaping the future of prostate cancer imaging. 🔗

🌍 Epidemiology of Renal Cancer by Alessandro Larcher et al. A global analysis of renal cancer trends reveals a steady increase in incidence and mortality, with more than 430,000 new cases and 155,000 deaths reported in 2022. 🔹 Obesity, smoking, and hypertension remain key

💡 Word of Wisdom - ARANOTE trial The ARANOTE trial reinforces the role of darolutamide + ADT as a well-tolerated, chemotherapy-free intensification strategy for metastatic hormone-sensitive prostate cancer. 🔹 Significant improvement in rPFS (HR 0.54, p < 0.0001) 🔹 Lower